OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
APGAR ScoreAssisted Delivery (FIGO)BPP (Manning Score)Bishop ScoreCARPREG II Cardiac RiskCervical Cancer StagingContraceptive Pearl IndexDoppler Matrix (UA/MCA)EFW (Hadlock)Endometrial StagingEndometrial ThicknessFGR Criteria (Consensus)FSFI (Sexual Function)Ferriman-Gallwey ScoreFetal Anemia (MCA PSV)GDM Diagnostic CriteriaGPA History IndicatorGail Model Breast RiskGestational Dating (LMP)HIV PMTCT ProtocolIOTA Simple RulesIVF Due Date & AMHIron Deficit (Ganzoni)Labour Progress (WHO)Maternal Sepsis (qSOFA)O-RADS ClassificationOvarian Cancer StagingPAS Hemorrhage RiskPPH Protocol (FIGO)Preeclampsia (ACOG)Rho(D) Dose (K-B)Rotterdam PCOS CriteriaSyphilis ManagementTORCH FrameworkVBAC Success ProbabilityVulvar Cancer StagingWeight Gain (IOM)mWHO Cardiac Risk

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Clinical Uses

  • Non-invasive screening for suspected fetal anemia (e.g., Rh/Kell alloimmunization)
  • Monitoring pregnancies at high risk for parvovirus B19 infection
  • Surveillance in cases of suspected twin-anemia polycythemia sequence (TAPS)

When NOT to Use

Predictive value drops precipitously after 35 weeks of gestation. Do NOT use MCA-PSV as the sole determinant for delivery timing in late preterm/term fetuses. False positive rates surge near term.

CLINICAL INSIGHT

How it Works

Pathophysiologic Basis

  • Fetal anemia reduces blood viscosity.
  • Anemia triggers a hyperdynamic circulatory state (increased cardiac output) to maintain tissue oxygenation.
  • The combination of thin blood and high output dramatically increases the peak systolic velocity (PSV) in the easily accessible Middle Cerebral Artery (MCA).

Standard Thresholds

< 1.5 MoM
≥ 1.5 MoM
≥ 1.55 MoM
CLINICAL INSIGHT

Practical Pearls

Measurement Precision Rules

  • Angle of insonation MUST be exactly 0 degrees. Any angle correction artificially alters the velocity readout and invalidates the algorithm.
  • Measurement must be taken in the proximal third of the MCA, near its origin from the internal carotid.
  • Avoid applying pressure to the maternal abdomen (fetal head compression artificially elevates velocity).
  • Fetal breathing or overt movement will alter velocity; measure during a period of fetal apnea/quiescence.
CLINICAL INSIGHT

Next Steps

Management of Elevated PSV (≥ 1.5 MoM)

  • Verify measurement meticulously (repeat sequentially).
  • If persistently ≥1.5 MoM and gestation < 35 weeks: Proceed to cordocentesis (Percutaneous Umbilical Blood Sampling - PUBS) for definitive hematocrit.
  • Prepare cross-matched, irradiated, O-negative packed red blood cells for immediate intrauterine transfusion (IUT) during PUBS if anemia is confirmed.
  • If ≥ 35 weeks: Consider expedited delivery rather than high-risk intrauterine transfusion.
CLINICAL INSIGHT

Evidence Base

Landmark Trial

Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization.

Mari G, et al.N Engl J Med.2000
CLINICAL INSIGHT

Background

Dr. Giancarlo Mari

Pioneered by Giancarlo Mari and the Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. It revolutionized maternal-fetal medicine by nearly eliminating the routine use of invasive, risk-heavy serial amniocenteses (Liley curves for delta OD450).

Fetal Anemia (MCA PSV)

MCA Peak Systolic Velocity

Fetal Anemia Surveillance (Mari et al.)

Clinical Note: MCA-PSV > 1.5 MoM is the evidence-based threshold for invasive testing (cordocentesis) or intrauterine transfusion in alloimmunized pregnancies.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Clinical Uses

  • Non-invasive screening for suspected fetal anemia (e.g., Rh/Kell alloimmunization)
  • Monitoring pregnancies at high risk for parvovirus B19 infection
  • Surveillance in cases of suspected twin-anemia polycythemia sequence (TAPS)

When NOT to Use

Predictive value drops precipitously after 35 weeks of gestation. Do NOT use MCA-PSV as the sole determinant for delivery timing in late preterm/term fetuses. False positive rates surge near term.

CLINICAL INSIGHT

How it Works

Pathophysiologic Basis

  • Fetal anemia reduces blood viscosity.
  • Anemia triggers a hyperdynamic circulatory state (increased cardiac output) to maintain tissue oxygenation.
  • The combination of thin blood and high output dramatically increases the peak systolic velocity (PSV) in the easily accessible Middle Cerebral Artery (MCA).

Standard Thresholds

< 1.5 MoM
≥ 1.5 MoM
≥ 1.55 MoM
CLINICAL INSIGHT

Practical Pearls

Measurement Precision Rules

  • Angle of insonation MUST be exactly 0 degrees. Any angle correction artificially alters the velocity readout and invalidates the algorithm.
  • Measurement must be taken in the proximal third of the MCA, near its origin from the internal carotid.
  • Avoid applying pressure to the maternal abdomen (fetal head compression artificially elevates velocity).
  • Fetal breathing or overt movement will alter velocity; measure during a period of fetal apnea/quiescence.
CLINICAL INSIGHT

Next Steps

Management of Elevated PSV (≥ 1.5 MoM)

  • Verify measurement meticulously (repeat sequentially).
  • If persistently ≥1.5 MoM and gestation < 35 weeks: Proceed to cordocentesis (Percutaneous Umbilical Blood Sampling - PUBS) for definitive hematocrit.
  • Prepare cross-matched, irradiated, O-negative packed red blood cells for immediate intrauterine transfusion (IUT) during PUBS if anemia is confirmed.
  • If ≥ 35 weeks: Consider expedited delivery rather than high-risk intrauterine transfusion.
CLINICAL INSIGHT

Evidence Base

Landmark Trial

Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization.

Mari G, et al.N Engl J Med.2000
CLINICAL INSIGHT

Background

Dr. Giancarlo Mari

Pioneered by Giancarlo Mari and the Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. It revolutionized maternal-fetal medicine by nearly eliminating the routine use of invasive, risk-heavy serial amniocenteses (Liley curves for delta OD450).